MODERN LOCAL GLAUCOMA TREATMENT AND PERSPECTIVES

  • Ugnė Žilinskaitė
  • Miglė Grinevičiūtė
  • Loreta Kuzmienė
Keywords: glaucoma

Abstract

Glaucoma is an eye disease that causes irreversible blindness, especially for the elderly. The major risk factor for glaucoma is intraocular pressure, the target of glaucoma treatment is to reduce intraocular pressure and prevent the progression of glaucoma [1, 2]. Glaucoma patients can be treated with intraocular pressure reduction eyesdrops, with laser procedural or surgery depending on the underlying cause and stage of the disease. If it is difficult to confirm the diagnosis of glaucoma, monitoring is required to assess whether glaucoma changes are occurring or progressing in order for the necessary treatment to be applied [3]. When diagnosed, the patient is prescribed with eyedrops that lower intraocular pressure. Several classes of localy applied antihypertensive medicinal products are distinguished: prostaglandin analogues, beta-receptor blockers, alpha-adrenergic receptor agonists, carbonic anhydrase inhibitors, and muscarinic receptor agonists [4]. However  widely eyedrops for treating glaucoma is used, causes adverse reactions for one thind of the patients [2].
This main group of drugs, its adverse reactions and the inovations in treating glaucoma based on recent literature are discussed in this article.

Published
2020-03-24
Section
Literature review